Am J Transplant, Volume 16, Suppl 3 Archives - Page 16 of 180 - ATC Abstracts

2016 American Transplant Congress
Significant Pharmacokinetic Interaction Between Everolimus and Tacrolimus in De Novo Renal Transplant Recipients.
H.-P. Chang,¹ C.-Y. Lee,² C.-C. Si,¹ M.-K. Tsai,² F.-L. Lin Wu.^1,3
¹Graduate Institute of Clinical Pharmacy, National Taiwan University, College of Medicine, Taipei, Taiwan; ²Surgery, National Taiwan University Hospital, College of Medicine, Taipei, Taiwan.
Studies on the effect of everolimus on tacrolimus pharmacokinetics (PK) were limited and the results were inconsistent. In contrast, studies showed there was little effect…
2016 American Transplant Congress
Outcomes of Hispanic Kidney Transplant Recipients Under a Cyclosporine versus Tacrolimus Based Immunosuppression Protocol.
P. West-Thielke, A. Lasky, J. Thielke, M. Campara, E. Benedetti.
University of Illinois, Chicago.
Purpose: In 2005, an internal retrospective study at our institution showed a higher incidence of post transplant diabetes mellitus (PTDM) in our Hispanic kidney transplant…
2016 American Transplant Congress
Elucidating Clinical Factors Implicated in Primary Graft Dysfunction After Heart Transplantation.
R. Quintana-Quezada, I. Rajapreyar, Y. Yeh, S. Choi, I. Gregoric, P. Loyalka, B. Kar.
Advanced Heart Failure, University of Texas Medical School at Houston, Houston, TX.
Primary graft dysfunction (PGD) is a frequent complication after heart transplantation (HT) and remains among the leading causes of mortality in these patients. We aim…
2016 American Transplant Congress
Using Gastrointestinal Biopsy to Predict Outcome in Patients Evaluated for Cardiac Transplantation for Amyloidosis: A Report from the International Consortium on Cardiac Amyloidosis Transplantation (iCCAT).
Y. Li,¹ K. Verkouw,¹ S. Tabtabai,¹ R. Barrios,² R. Gill,³ J. Koo,⁴ C. Marboe,⁵ E. Rodriguez,⁶ C. Tan,⁶ T. De Marco,³ J. Estep,² M. Hanna,⁶ M. Maurer,⁵ J. Patel,⁴ V. Selby,³ M. Semigran,¹ J. Stone.¹
¹Massachusetts General Hospital, Boston, MA; ²The Methodist Hospital, Houston, TX; ³University of California San Francisco, San Francisco, CA; ⁴Cedars-Sinai Heart Institute, Los Angeles, CA; ⁵Columbia University Medical Center, New York, NY; ⁶Cleveland Clinic, Cleveland, OH.
Heart transplant (HT) is an established therapy for heart failure due to amyloidosis. The utility of gastrointestinal (GI) biopsy in predicting patient outcomes and guiding…
2016 American Transplant Congress
Kidney Outcomes in Patients with Liver Cirrhosis and Chronic Kidney Disease Receiving an Orthotopic Liver Transplant Alone.
N. Singh,^1,2 S. Ahmadzadeh,¹ B. Amin,² R. Marahatta,² H. Shokouh-Amiri,¹ R. McMillan,¹ G. Zibari.¹
¹JOHN C. MCDONALD REGIONAL TRANSPLANT CENTER, Shreveport, LA; ²Division of Nephrology, Louisiana State University Health Sciences Center, Shreveport, LA.
Kidney Transplant in patients with liver cirrhosis and advanced CKD remains debatable. The 2012 simultaneous liver kidney transplant (SLKT) summit guidelines recommend SLKT in patients…
2016 American Transplant Congress
Risk Factors for Hospitalization Among Waitlisted End Stage Renal Disease Patients.
K. Newman,^1,2 A. Adams,² S. Pastan,² R. Lynch,² R. Zhang,¹ R. Patzer.^1,2
¹Emory University Rollins School of Public Health, Atlanta, GA; ²Emory University School of Medicine, Atlanta, GA.
Background: For End Stage Renal Disease Patients (ESRD) waitlisted for a deceased donor kidney, hospitalization is associated with lower likelihood of transplantation and worse outcomes.…
2016 American Transplant Congress
Alkaline Phosphatase a New Marker for Graft Outcome and High Pulse Wave Velocity in Renal Transplant Recipients.
S. Sezer,¹ E. Tutal,¹ Z. Bal,¹ B. Demirci,¹ M. Haberal.²
¹Nephrology, Baskent University Faculty of Medicine, Ankara, Turkey; ²General Surgery, Baskent University Faculty of Medicine, Ankara, Turkey.
Purpose: Alkaline phosphatase (ALP) is a marker of bone turnover which is widely used for estimating type of bone turnover in patients with end-stage renal…
2016 American Transplant Congress
Trends in Liver Transplant Rates and Waitlist Survival.
M. Bowring, A. Massie, X. Luo, L. Kucirka, E. Chow, A. Cameron, D. Segev.
JHU, Baltimore.
Long term changes in access to deceased-donor liver transplantation(DDLT) due to persistent growth of the waitlist, stagnant organ availability, and intermittent allocation policy changes have…
2016 American Transplant Congress
The Role of Obesity in Survival Outcomes of Liver Transplant Recipients with High MELD Score.
S.-H. Chang,¹ N. Carlsson,¹ X. Liu,² J. Wellen,³ J. Hagopian,⁴ T. Horwedel,⁴ T. Alhamad.⁵
¹Division of Public Health Sciences, Department of Surgery, Washington University in St. Louis, St. Louis; ²Division of Biostatistics, Washington University in St. Louis, St. Louis; ³Department of Surgery, Washington University in St. Louis, St. Louis; ⁴Department of Pharmacy, Barnes Jewish Hospital, St. Louis; ⁵Renal Division, Washington University, St. Louis.
Background:Obesity has become an epidemic in the United States. More than one third of adults are obese, defined as having body mass index (BMI) greater…
2016 American Transplant Congress
Liver Graft Steatosis Associates with an Increase of Circulating Immune Response Chemokines.
R. Gehrau, V. Mas, A. Sharma, V. Bontha, D. Maluf.
University of Virginia, Charlottesville.
Background: Liver graft steatosis, especially macrosteatosis induces severe graft injury post-liver transplantation (LT) by activating cell-mediated immunity and inflammation. This study aimed to determine differential…